Arcamone F, Bernardi L, Giardino P, Patelli B, Marco A, Casazza A M, Pratesi G, Reggiani P
Cancer Treat Rep. 1976 Jul;60(7):829-34.
Four new derivatives of daunorubicin, characterized by the absence of the methoxyl group at the C-4 position, have been obtained by chemical synthesis. 4-Demethoxydaunorubicin (NSC-256439) was effective against L1210 and Gross leukemias and ascites and solid Sarcoma 180 at doses four to eight times lower than those effective for daunorubicin. The beta anomer of 4-demethoxydaunorubicin was active at doses 13and eight times higher than those of its corresponding alpha anomer against L1210 and Gross leukemias respectively. 4-Demethoxy-7,9-diepidaunorubicin and its beta anomer were devoid of any biologic activity at the doses tested.
通过化学合成获得了四种柔红霉素的新衍生物,其特征是在C-4位没有甲氧基。4-去甲氧基柔红霉素(NSC-256439)对L1210白血病、格罗斯白血病、腹水型和实体型肉瘤180有效,其有效剂量比柔红霉素低四至八倍。4-去甲氧基柔红霉素的β异头物对L1210白血病和格罗斯白血病的有效剂量分别比其相应的α异头物高13倍和8倍。4-去甲氧基-7,9-二表柔红霉素及其β异头物在所测试的剂量下没有任何生物活性。